Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
The FDA's concerns cite peptide manufacturing risks: incompletely characterised active ingredient, peptide fragments, degradation products, and impurities that the immune system may recognise as foreign
AMPK: Sensing glucose as well as cellular energy status
10.1016/j.neuron.2019.05.035 69 KincaidB.Bossy-WetzelE
Ligand engineering and surface functionalization Target selectivity in GLP-1R-targeted nanoplatforms is achieved primarily by engineering the presentation of the peptide agonist or alternative affinity ligands on the carrier surface
US$ 22.18
US$ 23.56
US$ 24.59
US$ 28.39
US$ 29.21
US$ 29.91
